| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
INmune Bio Inc. (NASDAQ:INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the company's YouTube Channel following the conclusion of Alzheimer's Association International Conference (AAIC) in Toronto, Canada.
This forthcoming video will offer a comprehensive overview of the latest clinical insights shared during the Alzheimer's Association International Conference (AAIC). Viewers can expect an in-depth exploration of how XPro™ was evaluated within the MINDFuL study design, as well as the significance of the findings for patients, clinicians, and investors interested in the evolving landscape of Alzheimer's disease therapies.
The presentation at AAIC is scheduled in a Developing Topics session on Tuesday, July 29, 2025, from 2:00 to 3:30 PM ET in room 718 and the video will be available at 4PM ET on Thursday, July 31, 2025.
The MINDFuL trial is a double-blind, Phase 2 proof-of-concept study examining the potential of XPro™ to slow cognitive decline in early-stage Alzheimer's disease (AD) by targeting neuroinflammation. In the trial, changes in clinical measures of cognition, behavior, and AD-related biomarkers demonstrated a consistent benefit of treatment with XProTM after 6 months in a subpopulation of patients with amyloid-beta pathology and at least 2 of the blood biomarkers of inflammation.
